Treatment outcomes of small cell carcinoma of the prostate: A single-center study

Cancer

Volumn 110, Issue 8, 2007, Pages 1729-1737

  Spiess, Philippe E ^a   Pettaway, Curtis A ^a   Vakar Lopez, Funda ^a   Kassouf, Wassim ^a   Wang, Xuemei ^a   Busby, Joseph E ^a   Do, Kim Anh ^a   Davuluri, Rajayogesh ^a   Tannir, Nizar M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Diagnosis; Prognosis; Prostate cancer; Small cell carcinoma

Indexed keywords

ALBUMIN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ETOPOSIDE; LACTATE DEHYDROGENASE; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; FOLLOW UP; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LOCAL THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA; SMALL CELL CARCINOMA; SYSTEMIC THERAPY; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SERUM ALBUMIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 35048868879     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22971     Document Type: Article

References (23)

1. Wenk RE, Bhagavan BS, Levy R, et al. Ectopic ACTH, prostate oat cell carcinoma, and marked hypernatremia. Cancer. 1977;40:773-778.
2. Amato RJ, Logothetis CJ, Hallinan R, et al. Chemotherapy for small cell carcinoma of prostatic origin. J Urol. 1992;147:804-807.
3. Pearse AG, Takor T. Embryology of the diffuse neuroendocrine system and its relationship to the common peptides. Fed Proc. 1979;38:2288-2294.
4. Schron DS, Gipson T, Mendelsohn G. The histogenesis of small cell carcinoma of the prostate: an immunohistochemical study. Cancer. 1984;53:2478-2480.
5. Azzopardi JG, Evans DJ. Argentaffin cells in prostatic carcinoma: differentiation from lipofuscin and melanin in prostatic epithelium. J Pathol. 1971;104:247-251.
6. Helpap B, Kollermann J, Oehler U. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutic perspectives. Urol Int. 1999;62:133-138.
7. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological, and immunohistochemical study of 27 patients. J Urol. 1992;147:804-807.
8. Tetu B, Ro JY, Ayala AG, et al. Small cell carcinoma of the Prostate. Part I. A clinicopathologic study of 20 cases. Cancer. 1987;59:1803-1809.
9. Papandreou CN, Daliani DD, Thall PF, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002;20:3072-3080.
10. Kaplan GL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
11. Sato A, Ohigashi T, Oya M, et al. Clinicopathological features predicting nodal metastasis of testicular seminoma: results from 100 cases in a single institute. Urol Int. 2006;77:64-68.
12. Eggener SE, Yossepowitch O, Pettus JA, et al. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006;24:3101-3106.
13. Tas F, Aydiner A, Demir C, et al. Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small cell lung cancer. Am J Clin Oncol. 2001;24:376-378.
14. Cengiz O, Kocer B, Surmeli S, et al. Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma? Med Sci Monit. 2006;12:240-247.
15. Asmis TR, Reaume MN, Dahrouge S, et al. Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at the Ottawa Hospital Regional Cancer Center. BJU Int. 2006;97:711-715.
16. Evans CP, Busby JE, Kung HJ, et al. Neuroendocrine differentiation contributes to prostate cancer progression and the novel development of an in vivo neuroendocrine model. J Urol. 2003;169:89. Abstract 346.
17. Busby JE, Shih SJ, Yang JC, et al. Angiogenesis is not mediated by prostate cancer neuropeptides. Angiogenesis. 2004;6:289-293.
18. Rubenstein JH, Katin MJ, Mangano MM, et al. Small cell anaplastic carcinoma: 7 cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol. 1997;20:376-380.
19. Leibovici D, Spiess PE, Agarwal PK, et al. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer. 2006;109: 198-204.
20. Bunn PA Jr, Carney DN. Overview of chemotherapy for small cell lung cancer. Semin Oncol. 1997;S7:69-74.
21. Psyrri A, Murren J. Small cell lung cancer: strategies to optimize chemotherapy response. Cancer J. 2001;S1:28-34.
22. Siefker-Radtke AO, Dinney CP, Abrahams NA, et al. Evidence supporting pre-operative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol. 2004;172:481-484.
23. Siefker-Radtke AO, Kamat AM, Grossman HB, et al. Prospective evidence supporting the utility of neoadjuvant chemotherapy in small cell urothelial cancer: preliminary results from a phase II clinical trial at the M. D. Anderson Cancer Center. J Urol. 2006;175:399. Abstract 1240.